Pharvaris announced that deucrictibant met primary and secondary endpoints in a pivotal Phase III study as an on‑demand oral therapy for hereditary angioedema (HAE) attacks, reporting faster symptom relief and shorter time to complete resolution versus placebo. The company said it plans to file for regulatory approval in the first half of 2026 and highlighted metrics that compare favorably with an existing oral competitor. The results were reported in company releases and covered by MedCity News and industry outlets; analysts flagged the crowded but growing HAE market and emphasized the need for differentiated onset and durability data.